Cystine-glutamate antiporterxCTas a therapeutic target for cancer

被引：49

作者：

Liu, Lin ^{[1
]}

Liu, Rui ^{[2
]}

Liu, Yi ^{[1
]}

Li, Guanghui ^{[1
]}

Chen, Qing ^{[1
]}

Liu, Xiaodong ^{[1
]}

Ma, Shumei ^{[1
]}

机构：

[1] Wenzhou Med Univ, Platform Radiat Protect & Emergency Preparedness, Sch Publ Hlth & Management, Wenzhou 325035, Peoples R China

[2] Jilin Univ, Key Lab Radiobiol, Minist Hlth, Sch Publ Hlth, Changchun, Peoples R China

来源：

CELL BIOCHEMISTRY AND FUNCTION | 2021年 / 39卷 / 02期

关键词：

cancer; ferroptosis; oxidative stress; system X-c(-); xCT; CYSTINE/GLUTAMATE ANTIPORTER; CELL-PROLIFERATION; SYSTEM X(C)(-); XCT; FERROPTOSIS; CISPLATIN; INHIBITION; TRANSPORT; PROMOTES; SULFASALAZINE;

D O I：

10.1002/cbf.3581

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Cystine/glutamic acid reverse transporter (System X-c(-)), a member of the amino acid transporter family, consists of two subunits, light chain xCT and heavy chain 4F2hc. xCT is the cystine/glutamate antiporter solute carrier family 7 member 11 (SLC7A11), which promotes cystine uptake and glutathione biosynthetic, thus protecting against oxidative stress and ferroptosis. Studies have confirmed that xCT is highly expressed in a variety of tumour and is associated with tumour proliferation, invasion, metastasis, drug resistance and ferroptosis, and can be used as a potential target for tumour treatment. This review provides insights into the biological effects of xCT and contribute to the development of new xCT-based strategies.

引用

页码：174 / 179

页数：6

共 61 条

[1] Cystine-glutamate antiporter xCT deficiency suppresses tumor growth while preserving antitumor immunity
Arensman, Michael D.
Yang, Xiaoran S.
Leahy, Danielle M.
Toral-Barza, Lourdes
Mileski, Mary
Rosfjord, Edward C.
Wang, Fang
Deng, Shibing
Myers, Jeremy S.
Abraham, Robert T.
Eng, Christina H.
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (19) : 9533 - 9542
[2] Iron dyshomeostasis, lipid peroxidation and perturbed expression of cystine/glutamate antiporter in Alzheimer?s disease: Evidence of ferroptosis
Ashraf, Azhaar
Jeandriens, Jerome
Parkes, Harold G.
So, Po-Wah
[J]. REDOX BIOLOGY, 2020, 32
[3] Thinking Outside the Cleft to Understand Synaptic Activity: Contribution of the Cystine-Glutamate Antiporter (System xc-) to Normal and Pathological Glutamatergic Signaling
Bridges, Richard
Lutgen, Victoria
Lobner, Doug
Baker, David A.
[J]. PHARMACOLOGICAL REVIEWS, 2012, 64 (03) : 780 - 802
[4] System xc- cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS
Bridges, Richard J.
Natale, Nicholas R.
Patel, Sarjubhai A.
[J]. BRITISH JOURNAL OF PHARMACOLOGY, 2012, 165 (01) : 20 - 34
[5] ATF4 promotes angiogenesis and neuronal cell death and confers ferroptosis in a xCT-dependent manner
Chen, D.
Fan, Z.
Rauh, M.
Buchfelder, M.
Eyupoglu, I. Y.
Savaskan, N.
[J]. ONCOGENE, 2017, 36 (40) : 5593 - 5608
[6] NRF2 Is a Major Target of ARF in p53-Independent Tumor Suppression
Chen, Delin
Tavana, Omid
Chu, Bo
Erber, Luke
Chen, Yue
Baer, Richard
Gu, Wei
[J]. MOLECULAR CELL, 2017, 68 (01) : 224 - +
[7] Disruption of xCT inhibits cancer cell metastasis via the caveolin-1/β-catenin pathway
Chen, R-S
Song, Y-M
Zhou, Z-Y
Tong, T.
Li, Y.
Fu, M.
Guo, X-L
Dong, L-J
He, X.
Qiao, H-X
Zhan, Q-M
Li, W.
[J]. ONCOGENE, 2009, 28 (04) : 599 - 609
[8] Clemons NJ, 2017, MOL CELL ONCOL, V4, DOI 10.1080/23723556.2017.1344757
[9] Genetic Ablation of the Cystine Transporter xCT in PDAC Cells Inhibits mTORC1, Growth, Survival, and Tumor Formation via Nutrient and Oxidative Stresses
Daher, Boutaina
Parks, Scott K.
Durivault, Jerome
Cormerais, Yann
Baidarjad, Hanane
Tambutte, Eric
Pouyssegur, Jacques
Vucetic, Milica
[J]. CANCER RESEARCH, 2019, 79 (15) : 3877 - 3890
[10] SLC3A2/CD98hc, autophagy and tumor radioresistance: a link confirmed
Digomann, David
Linge, Annett
Dubrovska, Anna
[J]. AUTOPHAGY, 2019, 15 (10) : 1850 - 1851

← 1 2 3 4 5 6 7 →